AB Science S.A (AB) - Total Liabilities
Based on the latest financial reports, AB Science S.A (AB) has total liabilities worth €34.34 Million EUR (≈ $40.15 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See how many days can AB Science S.A fund operations to measure how many days the company can operate on defensive assets alone.
AB Science S.A - Total Liabilities Trend (2009–2025)
This chart illustrates how AB Science S.A's total liabilities have evolved over time, based on quarterly financial data. Check AB Science S.A liquid asset ratio to evaluate the company's liquid asset resilience ratio.
AB Science S.A Competitors by Total Liabilities
The table below lists competitors of AB Science S.A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yunsa Yunlu Sanayi ve Ticaret AS
IS:YUNSA
|
Turkey | TL1.52 Billion |
|
Aureus Greenway Holdings Inc. Common Stock
NASDAQ:AGH
|
USA | $2.04 Million |
|
Allcargo Terminals Ltd
NSE:ATL
|
India | Rs8.96 Billion |
|
Aminologics Co.Ltd
KQ:074430
|
Korea | ₩31.28 Billion |
|
Sun Brothers Development Co Ltd
TWO:3489
|
Taiwan | NT$3.29 Billion |
|
Samsung Climat
KO:006660
|
Korea | ₩45.28 Billion |
|
Quality Houses Hotel and Residence Freehold and Leasehold Property Fund
BK:QHHR
|
Thailand | ฿1.40 Billion |
|
Mobiis Co. Ltd
KQ:250060
|
Korea | ₩6.34 Billion |
Liability Composition Analysis (2009–2025)
This chart breaks down AB Science S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of AB Science S.A.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AB Science S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AB Science S.A (2009–2025)
The table below shows the annual total liabilities of AB Science S.A from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €34.34 Million ≈ $40.15 Million |
-26.83% |
| 2024-12-31 | €46.93 Million ≈ $54.86 Million |
+0.90% |
| 2023-12-31 | €46.51 Million ≈ $54.37 Million |
-21.85% |
| 2022-12-31 | €59.51 Million ≈ $69.57 Million |
+33.83% |
| 2021-12-31 | €44.47 Million ≈ $51.99 Million |
-9.68% |
| 2020-12-31 | €49.24 Million ≈ $57.56 Million |
+10.47% |
| 2019-12-31 | €44.57 Million ≈ $52.11 Million |
+19.00% |
| 2018-12-31 | €37.45 Million ≈ $43.79 Million |
-6.05% |
| 2017-12-31 | €39.87 Million ≈ $46.61 Million |
-6.67% |
| 2016-12-31 | €42.72 Million ≈ $49.94 Million |
-14.29% |
| 2015-12-31 | €49.84 Million ≈ $58.26 Million |
+6.13% |
| 2014-12-31 | €46.96 Million ≈ $54.90 Million |
+8.47% |
| 2013-12-31 | €43.29 Million ≈ $50.61 Million |
+72.59% |
| 2012-12-31 | €25.08 Million ≈ $29.32 Million |
+15.42% |
| 2011-12-31 | €21.73 Million ≈ $25.41 Million |
+48.69% |
| 2010-12-31 | €14.62 Million ≈ $17.09 Million |
+12.04% |
| 2009-12-31 | €13.04 Million ≈ $15.25 Million |
-- |
About AB Science S.A
AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company's lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyo… Read more